Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases

Human Immunology

Volumn 70, Issue 7, 2009, Pages 532-535

  Fernández Mestre, Mercedes ^a   Sánchez, Karen ^a   Balbás, Omar ^a   Gendzekhzadze, Ketevan ^a,b   Ogando, Violeta ^a   Cabrera, Mayra ^c   Layrisse, Zulay ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTO DE BIOMEDICINA   (Venezuela)

Author keywords

Autoimmune disease; CTLA 4; Gene polymorphism; Infectious disease

Indexed keywords

ADENINE; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GUANINE; INTERLEUKIN 2;

ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CHAGAS DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENGUE; DENGUE VIRUS; DISEASE PREDISPOSITION; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; IMMUNE RESPONSE; INFECTION; LEISHMANIA; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MYASTHENIA GRAVIS; PEMPHIGUS; PRIORITY JOURNAL; PSORIASIS; REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN LEISHMANIASIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRYPANOSOMA CRUZI;

ALLELES; ANTIGENS, CD; AUTOIMMUNE DISEASES; CHAGAS DISEASE; COMMUNICABLE DISEASES; DENGUE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEISHMANIASIS, CUTANEOUS; MYASTHENIA GRAVIS; PEMPHIGUS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSORIASIS; RISK FACTORS;

EID: 67449126847     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.03.016     Document Type: Article

References (33)

1. Wang X.B., Zhao X., Giscombe R., and Lefvert A.K. A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun 3 (2002) 233-234
2. Gavin M., and Rudensky A. Control of immune homeostasis by naturally arising regulatory CD4+ T cells. Curr Opin Immunol 15 (2003) 690-696
3. Johnson G.C., Esposito L., Barratt B.J., Smith A.N., Heward J., Di Genova G., et al. Haplotype tagging for the identification of common disease genes. Nat Genet 29 (2001) 233-237
4. Kouki T., Sawai Y., Gardine C., Fisfalen M., Alegre M., and DeGroot L. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 165 (2000) 6606-6611
5. Mäurer M., Mäurer M., Loserth S., Kolb-Mäurer A., Ponath A., Wiese S., et al. Polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 54 (2002) 1-8
6. Kristiansen O.P., Larsen Z.M., and Pociot F. CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity?. Genes Immun 1 (2000) 170-184
7. Anonymous. Dengue hemorrhagic fever. Diagnosis, treatment, prevention and control (1997), World Health Organization, Geneva pp 1-84.
8. Acquatella H., Catalioti F., Gomez-Mancebo J.R., Davalos V., and Villalobos L. Long term control of Chagas disease in Venezuela: effects on serological findings, electrocardiographic abnormalities, and clinical outcome. Circulation 76 (1987) 556-562
9. Convit J., and Pinardi M. Cutaneous leishmaniasis. The clinical and immunopathological spectrum in South America (1974), ASP, Amsterdam 160-6.
10. Bunce M. In: Lidwell, and Navarrette C. (Eds). In Histocompatibility testing (2000), Imperial College Press, London 167-760
11. Deichmann K., Heinzmann A., Bruggenolte E., Forster J., and Kuehr J. An MseI RFLP in the human CTLA4 promoter. Biochem Biophys Res Commun 225 (1996) 817-818
12. Hudson L., Rocca K., Song Y., and Pandey J. CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet 111 (2002) 452-455
13. Svejgaard A., and Ryder L.P. HLA and disease associations: detecting the strongest association. Tissue Antigens 43 (1994) 18-27
14. Woolf B. On estimating the relation between blood group and disease. Ann Human Genet 19 (1995) 251-253
15. Haldane J.B.S. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet 20 (1956) 309-311
16. Berry A., Tector M., and Oaks M.K. Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms. J Negative Results BioMed 7 (2008) 8-11
17. Wang H.B., Shi F.D., Li H., Chambers B.J., Link H., and Ljunggren H.G. Anti-CTLA-antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 166 (2001) 6430-6436
18. Huang D., Liu L., Noren K., Xia S.Q., Trifunovic J., Pirskanen R., et al. Genetic association of CTLA-4 to myasthenia gravis with thymoma. J Neuroimmunol 88 (1998) 182-198
19. Huang D., Giscombe R., Zhou Y., Pirskanen R., and Lefvert A.K. Dinucleotide repeat expansion in the CTLA-4 gene leads to T-cell hyperreactivity via the CD28 pathway in myasthenia gravis. J Neuroimmunol 105 (2000) 68-77
20. Wang X.B., Kakoulidou M., Giscombe R., Qiu Q., Huang D., Pirskanen R., et al. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 130 (2002) 224-232
21. Pavoni D.P., Cerqueira L.B., Roxo V.M., and Petzl-Erler M.L. Polymorphism of the promoter region and exon 1 of the CTLA-4 gene in endemic pemphigus foliaceus (fogo selvagem). Braz J Med Biol Res 39 (2006) 1227-1232
22. Khoury S.J., and Sayegh M.H. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2 (2004) 529-538
23. Carreno B.M., Bennett F., Chau T.A., Ling V., Luxenberg D., Jussif J., et al. CTLA-4 (CD152) can inhibit T-cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 165 (2000) 1352-1356
24. Riley J.L., and June C.H. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 105 (2005) 13-21
25. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103 (1999) 1243-1252
26. Luszczek W., Kubicka W., Jasek M., Baran E., et al. CTLA-4 gene polymorphisms and natural soluble CTLA-4 protein in psoriasis vulgaris. Int Immunogenet 33 (2006) 217-224
27. Wang X.B., Pirskanen R., Giscombe R., and Lefvert A.K. Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J Intern Med 263 (2008) 61-67
28. Bach J.F. [Infections and autoimmunity. ] Rev Med Interne 1 (2005) 32-34
29. Correa P.A., Gomez L.M., Cadena J., and Anaya J.M. Autoimmunity and tuberculosis. Opposite association with TNF polymorphism. J Rheumatol 32 (2005) 219-224
30. Diaz N.L., Arveláez A., Zerpa O., and Tapia F.T. Inducible nitric oxide synthase and cytokine pattern in lesions of patients with American cutaneous leishmaniasis. Exp Dermatol 31 (2005) 114-117
31. Favali C., Costa D., Afonso L., Conceição V., Rosato A., Oliveira F., et al. Role of costimulatory molecules in immune response of patients with cutaneous leishmaniasis. Microbes Infect 7 (2005) 86-92
32. Ubaldi V., Gatta L., Pace L., Doria G., and Pioli C. CTLA-4 engagement inhibits Th2 but not Th1 cell polarization. Clin Dev Immunol 10 (2003) 13-17
33. Ulrich M., Rodríguez V., Centeno M., and Convit J. Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen-specific T cell anergy. Clin Exp Immunol 100 (1995) 54-58